Printer Friendly
The Free Library
19,585,952 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

BioSyntech Signs Cato Research as BST-CarGel'R' Clinical Trial CRO.


LAVAL, Quebec -- BIOSYNTECH (TSX Venture Exchange TSX Venture Exchange

Originally called the Canadian Venture Exchange (CDNX), this was a result of the merger of the Vancouver and Alberta stock exchanges. The goal of TSX Venture Exchange is to provide venture companies with effective access to capital while protecting investors.
:BSY BSY Busy
BSY British School of Yoga
BSY Bit Sync
BSY Busy Line
) is pleased to announce the signing of a Master Service Agreement with Cato Research Ltd., a contract research organization (CRO) that will support BioSyntech in their upcoming BST-CarGel(R) clinical trials.

This important selection followed a rigorous screening of several CROs, wherein BioSyntech pinpointed the essential capabilities and experience that will be critical for bringing a unique product like BST-CarGel(R) through the clinical testing phase.Cato Research will perform the study setup and protocol review, monitoring, project management, data management, statistics and medical writing for the BST-CarGel clinical trials.This will ensure that the protocol and the study conduct adhere to regulatory requirements and that the outcomes are accepted by regulatory agencies.

Headquartered in Research Triangle Park Research Triangle Park, research, business, medical, and educational complex situated in central North Carolina. It has an area of 6,900 acres (2,795 hectares) and is 8 × 2 mi (13 × 3 km) in size. Named for the triangle formed by Duke Univ. , North Carolina North Carolina, state in the SE United States. It is bordered by the Atlantic Ocean (E), South Carolina and Georgia (S), Tennessee (W), and Virginia (N). Facts and Figures


Area, 52,586 sq mi (136,198 sq km). Pop.
, with an office in Montreal, Cato Research is well suited to execute a successful clinical program bringing both quality and cost-effectiveness to BioSyntech studies.

"BioSyntech's strategic plan is focused on maximizing the label indications for our products so we can maximize the value of our products," said Claude LeDuc, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board.  of BioSyntech. "The selection of Cato will bring BST-CarGel through a major clinical testing phase and one step closer towards general availability, for the benefit of millions of potential patients."

Following approval from Health Canada and European authorities, BioSyntech will initiate a multi-center Canadian-European clinical trial, and Cato Research will provide the needed infrastructure for such a large study.The clinical team is being assembled, and currently consists of internationally recognized orthopaedic opinion leaders, all highly experienced and motivated.These key physicians are associated with some of the most respected orthopaedic centers in Canada and Europe, including in Toronto, London (Ontario), Calgary, Winnipeg,Montreal, France and Germany.

BST-CarGel(R), a cartilage repair product, is the first product in a new category called Scaffold Guided Regenerative Medicine (SGRM) using a process called In Situ Chondro-Induction (ICI (language) ICI - An extensible, interpretated language by Tim Long with syntax similar to C. ICI adds high-level garbage-collected associative data structures, exception handling, sets, regular expressions, and dynamic arrays. ), which means that BioSyntech's BST-CarGel(R) technology aims to regenerate cartilage directly in the patient's lesion rather than in a laboratory.

About BioSyntech - BioSyntech is a biotechnology company specializing in the discovery, development and manufacturing of innovative cost-effective and physician-friendly biologic-implants for regenerative medicine and therapeutic delivery.BioSyntech's Quality Management System is registered to ISO (1) See ISO speed.

(2) (International Organization for Standardization, Geneva, Switzerland, www.iso.ch) An organization that sets international standards, founded in 1946. The U.S. member body is ANSI.
 9001:2000 and ISO 13485:2001. For additional information, visit www.biosyntech.com.

About Cato Research - Cato Research is a global contract research and development organization with offices in Canada, U.S., Europe, Israel and South Africa, offering a full range of research services for the development of drugs, medical devices and biologics. For additional information, visit www.cato.com.

NO REGULATORY AUTHORITY HAS APPROVED OR DISAPPROVED THE CONTENT OF THIS RELEASE. THE TSX VENTURE EXCHANGE DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

BIOSYNTECH INC inc - /ink/ increment, i.e. increase by one. Especially used by assembly programmers, as many assembly languages have an "inc" mnemonic.

Antonym: dec.
. (TSX TSX Toronto Stock Exchange (TSE before April, 2002)
TSX Transfer from Stack Pointer to Index
TSX True Space Extension
 VENTURE:BSY)
COPYRIGHT 2004 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Sep 1, 2004
Words:462
Previous Article:'Nextel Prepared' Awards Honor Leaders in Public Safety.
Next Article:CEOs Billy Prim and Christy Shaffer to Keynote Entrepreneur '04; CED Also Announces Initial Panel Details for Oct. 30 Conference.



Related Articles
BIOSYNTECH/BIOMET TO DEVELOP NEW HARD TISSUE HEALING.
BIOSYNTECH REPORTS SUCCESSFUL SAFETY EVALUATION OF BST-GEL.
BioSyntech Inc.: Dr. Michael Buschmann to Receive the Innovator Prize for 2004 from ADRIQ.
BioSyntech Receives First Tranche of $1 Million From La Financiere du Quebec, Provides Shareholder Update On Projects.
Clinical Research organizations offer wide range of management opportunities for physician executives.
BioSyntech Signs Agreement with MedQualis as BST-DermOn'TM' and BST-InPod'TM' Clinical Trial CRO...
BioSyntech Receives Approval for Canadian BST-Cargel'R' Pivotal Clinical Trial.
BioSyntech Reports its Second Quarter Result.
AGREX, CRONOVA to Join Hands in CRO Business.
SPHERIX SIGNS ANACLIM TO SUPPORT DIABETES CLINICAL TRIAL.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles